PureTech Health announced that enrollment has been completed in the ELEVATE IPF Phase 2b clinical trial evaluating LYT-100 in patients with idiopathic pulmonary fibrosis, or IPF.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTC:
- PureTech gets FDA fast track designation for LYT-200 to treat head/neck cancer
- PureTech Health Debuts Seaport Therapeutics and Reshuffles Leadership
- PureTech Health Announces $100 Million Shareholder Return
- PureTech Health announces proposed capital return of $100M
- PureTech Health Entity Acquired for $14 Billion